A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live <i>Bifidobacterium longum</i> CECT 7347 (ES1) and heat-treated <i>Bifidobacterium longum</i> CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome-Reference-Cited by-同舟云学术

A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live Bifidobacterium longum CECT 7347 (ES1) and heat-treated Bifidobacterium longum CECT 7347 (HT-ES1) in participants with diarrhea-predominant irritable bowel syndrome

Published:2024-04-17 Issue:1 Volume:16 Page:
ISSN:1949-0976
Container-title:Gut Microbes
language:en
Short-container-title:Gut Microbes

Author:

Srivastava S¹,Basak U¹,Naghibi M²,Vijayakumar V²,Parihar R³,Patel J⁴,Jadon PS⁵,Pandit A⁶,Dargad RR⁷,Khanna S⁸,Kumar S⁹,Day R²

Affiliation:

1. Clinical Development & Science Communications, Vedic Lifesciences Pvt Ltd, Mumbai, India

2. Medical Department, ADM Health & Wellness, London, UK

3. Gastroenterology Department, Gastroplus Digestive Disease Centre, Ahmedabad, India

4. Gastroenterology Department, Apex Gastro Clinic and Hospital, Ahmedabad, India

5. Medicine Department, Jaipur National University Institute for Medical Science & Research Centre, Jaipur, India

6. General Surgery Department, United Multispeciality Hospital, Maharashtra, India

7. Medicine Department, Lilavati Hospital & Research Centre, Maharashtra, India

8. Gastroenterology Department, Criticare Asia Multispeciality hospital, Maharashtra, India

9. Independent Biostatistical Consultant, Delhi, India

Funder

This study received funding from ADM. The funder had the following involvement with the study: study design, writing and reviewing of the manuscript. MN, VV and RD are employed by ADM

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/19490976.2024.2338322

Reference33 articles.

1. Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine

3. Irritable Bowel Syndrome

4. Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysis

5. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study